Safety & Efficacy Study of Epcoritamab in Subjects With R/R Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE CLL-1)

  • End date
    Aug 30, 2026
  • participants needed
  • sponsor
Updated on 30 June 2022


The trial is an open-label, multi-center safety and efficacy trial of epcoritamab in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and Ritcher's Syndrome (RS). The trial consists of two parts, a dose escalation phase (phase Ib) and an expansion phase (phase II).


The purpose of the escalation phase of the trial is to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (MTD; if reached) as well as establish the safety profile of epcoritamab in patients with R/R CLL.

In the expansion phase, additional patients will be treated with epcoritamab at the RP2D and the purpose is to assess and evaluate the preliminary efficacy, safety and tolerability profiles of epcoritamab at the RP2D for R/R CLL and RS.

Condition Relapsed/Refractory Chronic Lymphocytic Leukemia, Richter's Syndrome
Treatment Epcoritamab
Clinical Study IdentifierNCT04623541
Last Modified on30 June 2022


Yes No Not Sure

Inclusion Criteria

Subject must sign an ICF and be at least 18 years of age
ECOG performance status score of 0, 1 or 2
Screening evidence of CD20 positivity
Has laboratory parameters - HBG-≥9.0 g/dL; ANC-≥1.0 x 109/L; Platelets-≥30 x 109/L
A woman must not be of childbearing potential and practicing a highly effective method of birth control, with a negative serum beta-hCG and urine pregnancy test at screening
Received a cumulative dose of corticosteroids less than the equivalent of 250 mg of prednisone within the 2-week period before the first dose
For R/R CLL Cohort - Must have active CLL disease requiring treatment per iwCLL2018
Availability of fresh bone marrow material
For R/R CLL Cohort - received at least 2 prior lines of systemic anti-neoplastic therapy anti-neoplastic therapy including a BTK inhibitor
For R/R CLL Cohort - Measurable Disease ≥5 × 109/L (5,000/μL) B lymphocytes in peripheral blood or Presence of measurable lymphadenopathy and/or organomegaly
For RS Cohort - Documented clinical history transformation to diffuse large B cell lymphoma (DLBCL)
A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control
For RS Cohort - Not eligible for chemoimmunotherapy
For RS Cohort - must have detectable disease by PET scan and measurable by CT scan or MRI

Exclusion Criteria

Received prior treatment with a CD3 × CD20 bispecific antibody
Received any prior allogeneic HSCT or solid organ transplantation
Received treatment with an anti-cancer biologic including anti-CD20 therapy, radio-conjugated or toxin-conjugated antibody or CAR T-cell therapy or investigational drug within 2 weeks
Received chemotherapy or radiation therapy within 2 weeks of the first dose of epcoritamab
Concomitant disease requiring permanent or high-dose immunosuppressive therapy
Received vaccination with live vaccines within 28 days prior to the first dose of epcoritamab
Clinically significant cardiac disease
Major surgery within 4 weeks
Hepatitis B or C seropositivity (unless clearly due to vaccination)
History of human immunodeficiency virus (HIV)
Unable or unwilling to comply with contraceptive requirements during treatment and for 12 months after last dose of of epcoritamab
For R/R CLL Cohort - Any history of RS or evidence indicating a potential Richter's transformation
For RS Cohort - Transformation of CLL to Hodgkin variant of RS
For RS Cohort - Diagnosis of Richter's syndrome not of the DLBCL subtype such as Hodgkin's lymphoma, prolymphocytic leukemia
For RS Cohort - Subject received autologous HSCT within 3 months prior to the first dose of epcoritamab
For RS Cohort - Subject received more than 1 prior line of therapy for RS
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note